Cyclophosphamide is an oncological therapeutic compound whose cytotoxic mechanism—DNA alkylation, topoisomerase inhibition, antimitotic activity, or targeted kinase inhibition—produces tumour cell death or growth arrest at concentrations achievable clinically. The therapeutic index of Cyclophosphamide is narrow, with effective antitumour doses closely approaching doses producing unacceptable toxicity to normal host tissues. In pharmaceutical manufacturing, Cyclophosphamide is classified in the highest occupational hazard band based on its combination of pharmacological potency, genotoxic classification under ICH M7, and demonstrated systemic toxicity in preclinical and clinical studies.
Cleaning validation acceptance criteria for Cyclophosphamide in shared pharmaceutical equipment are determined using the health-based MACO formula: MACO (mg/batch) = PDE(mg/day) × MBS(g) ÷ TDD(g/day), where MBS is the minimum batch size of the next product and TDD its maximum daily therapeutic dose.
